Global Tuberculosis Diagnostics research

Tuberculosis Diagnostics Comprehensive Study by Test (Radiographic Method, Diagnostic Laboratory Methods, Nucleic Acid Testing, Phage Assay, Detection of Latent Infection, Cytokine Detection Assay, Detection of Drug Resistance), End User (Hospital/Clinics, Diagnostics/Research Laboratory, Others) Players and Region - Global Market Outlook to 2030

Tuberculosis Diagnostics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Tuberculosis Diagnostics
Tuberculosis (TB) refers to an airborne infectious disease caused by Mycobacterium tuberculosis (MTB) bacteria. Common symptoms of this disease are cough for three or more weeks, chest pain, fever, fatigue, weight loss, and others. The increasing number of patients with tuberculosis driving the demand for a novel treatment for tuberculosis diagnostic. For instance, according to the World Health Organization in 2017, 10 million people affected by tuberculosis and 1.6 million death are recorded from this disease. And over 54 million patients are saved from tuberculosis diagnosis and treatment between 2000 and 2017. Further, increasing investment in healthcare infrastructure in developing countries expected to drive the demand for Lyme disease diagnostic market over the forecasted period.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Number of players are present in the market hence fragmented nature if the market. The increasing number of TB patients driving the demand for innovative tuberculosis diagnostic test. For instance, according to the Centers of Disease Control and Prevention in 2017, 9,105 TB cases were reported in the United States alone. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Tuberculosis Diagnostics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Thermo Fisher Scientific, Inc. (United States), Hologic Corporation (United States), Abbott Laboratories (United States), Alere, Inc., Becton (United States), Pfizer Inc. (United States), Johnson & Johnson (United States), Dickinson and Company (United States), F. Hoffmann-La Roche AG (Switzerland), Cepheid (United States), Mylan N.V (United States) and Hain Life science GmbH (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Eli Lilly and Company (United States), Qiagen (Germany), BioMerieux SA (France) and Sanofi (France).

Segmentation Overview
AMA Research has segmented the market of Global Tuberculosis Diagnostics market by and Region.



On the basis of geography, the market of Tuberculosis Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Test , the sub-segment i.e. Radiographic Method will boost the Tuberculosis Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User , the sub-segment i.e. Hospital/Clinics will boost the Tuberculosis Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growth in R&D towards New Drug Development and Emphasizing on Awareness Campaigns about the Importance of Diagnosis

Market Growth Drivers:
Increasing Prevalence of Tuberculosis and Government Initiatives to Control the Proliferation of Tuberculosis

Challenges:
Inability to Identify the Initial Symptoms of Tuberculosis

Restraints:
High Initial Investment for Laboratory Setup of Tuberculosis Diagnosis and Lack of Awareness Regarding Tuberculosis in Emerging Economies

Opportunities:
Growing Healthcare Infrastructure in the Developing Economies and Rising Awareness about Early Diagnosis and Treatment

Market Leaders and their expansionary development strategies
In August 2023, The Bill & Melinda Gates Foundation joins forces with Unitaid to fund the expansion of access to GeneXpert MTB/RIF Ultra tests in high-burden countries.
In October 2023, FIND launches its "TrueNat MDR assay," enabling detection of multidrug-resistant TB (MDR-TB) directly from sputum samples, streamlining diagnosis and optimizing treatment strategies.
According to the Food and Drug Administration regulations which address the mitigation of risks specific to the detection of the genetic mutations associated with antibiotic resistance of MTB-complexthe are as follows. The device must include an external positive assay control as appropriate. Acceptable positive assay controls include MTB-complex isolates containing one or more antibiotic-resistance associated target sequences detected by the device. The device's intended use must include a description of the scope of antibiotic resistance targeted by the assay. The specific performance characteristics section of the device's labeling must include information regarding the specificity of the assay oligonucleotides for detecting mutations associated with antibiotic resistance of MTB-complex.

Key Target Audience
Academic Institutes, Research Institutes, Reference Laboratories, Diagnostics Suppliers, Healthcare Association, Potential Investors, Government Organization, Market Research Firms and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Test
  • Radiographic Method
  • Diagnostic Laboratory Methods
  • Nucleic Acid Testing
  • Phage Assay
  • Detection of Latent Infection
  • Cytokine Detection Assay
  • Detection of Drug Resistance

By End User
  • Hospital/Clinics
  • Diagnostics/Research Laboratory
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Tuberculosis
      • 3.2.2. Government Initiatives to Control the Proliferation of Tuberculosis
    • 3.3. Market Challenges
      • 3.3.1. Inability to Identify the Initial Symptoms of Tuberculosis
    • 3.4. Market Trends
      • 3.4.1. Growth in R&D towards New Drug Development
      • 3.4.2. Emphasizing on Awareness Campaigns about the Importance of Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tuberculosis Diagnostics, by Test , End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Tuberculosis Diagnostics (Value)
      • 5.2.1. Global Tuberculosis Diagnostics Region
        • 5.2.1.1. South America
          • 5.2.1.1.1. Brazil
          • 5.2.1.1.2. Argentina
          • 5.2.1.1.3. Rest of South America
        • 5.2.1.2. Asia Pacific
          • 5.2.1.2.1. China
          • 5.2.1.2.2. Japan
          • 5.2.1.2.3. India
          • 5.2.1.2.4. South Korea
          • 5.2.1.2.5. Taiwan
          • 5.2.1.2.6. Australia
          • 5.2.1.2.7. Rest of Asia-Pacific
        • 5.2.1.3. Europe
          • 5.2.1.3.1. Germany
          • 5.2.1.3.2. France
          • 5.2.1.3.3. Italy
          • 5.2.1.3.4. United Kingdom
          • 5.2.1.3.5. Netherlands
          • 5.2.1.3.6. Rest of Europe
        • 5.2.1.4. MEA
          • 5.2.1.4.1. Middle East
          • 5.2.1.4.2. Africa
        • 5.2.1.5. North America
          • 5.2.1.5.1. United States
          • 5.2.1.5.2. Canada
          • 5.2.1.5.3. Mexico
  • 6. Tuberculosis Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hologic Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Alere, Inc., Becton (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dickinson and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cepheid (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Hain Life science GmbH (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Tuberculosis Diagnostics Sale, by Test , End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Tuberculosis Diagnostics (Value)
      • 7.2.1. Global Tuberculosis Diagnostics Region
        • 7.2.1.1. South America
          • 7.2.1.1.1. Brazil
          • 7.2.1.1.2. Argentina
          • 7.2.1.1.3. Rest of South America
        • 7.2.1.2. Asia Pacific
          • 7.2.1.2.1. China
          • 7.2.1.2.2. Japan
          • 7.2.1.2.3. India
          • 7.2.1.2.4. South Korea
          • 7.2.1.2.5. Taiwan
          • 7.2.1.2.6. Australia
          • 7.2.1.2.7. Rest of Asia-Pacific
        • 7.2.1.3. Europe
          • 7.2.1.3.1. Germany
          • 7.2.1.3.2. France
          • 7.2.1.3.3. Italy
          • 7.2.1.3.4. United Kingdom
          • 7.2.1.3.5. Netherlands
          • 7.2.1.3.6. Rest of Europe
        • 7.2.1.4. MEA
          • 7.2.1.4.1. Middle East
          • 7.2.1.4.2. Africa
        • 7.2.1.5. North America
          • 7.2.1.5.1. United States
          • 7.2.1.5.2. Canada
          • 7.2.1.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. South America Tuberculosis Diagnostics, by Country USD Million (2018-2023)
  • Table 2. South America Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 3. South America Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 4. Brazil Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 5. Brazil Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 6. Argentina Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 7. Argentina Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 8. Rest of South America Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 9. Rest of South America Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 10. Asia Pacific Tuberculosis Diagnostics, by Country USD Million (2018-2023)
  • Table 11. Asia Pacific Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 12. Asia Pacific Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 13. China Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 14. China Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 15. Japan Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 16. Japan Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 17. India Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 18. India Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 19. South Korea Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 20. South Korea Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 21. Taiwan Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 22. Taiwan Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 23. Australia Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 24. Australia Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 25. Rest of Asia-Pacific Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 26. Rest of Asia-Pacific Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 27. Europe Tuberculosis Diagnostics, by Country USD Million (2018-2023)
  • Table 28. Europe Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 29. Europe Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 30. Germany Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 31. Germany Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 32. France Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 33. France Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 34. Italy Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 35. Italy Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 36. United Kingdom Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 37. United Kingdom Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 38. Netherlands Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 39. Netherlands Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 40. Rest of Europe Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 41. Rest of Europe Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 42. MEA Tuberculosis Diagnostics, by Country USD Million (2018-2023)
  • Table 43. MEA Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 44. MEA Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 45. Middle East Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 46. Middle East Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 47. Africa Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 48. Africa Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 49. North America Tuberculosis Diagnostics, by Country USD Million (2018-2023)
  • Table 50. North America Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 51. North America Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 52. United States Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 53. United States Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 54. Canada Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 55. Canada Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 56. Mexico Tuberculosis Diagnostics, by Test USD Million (2018-2023)
  • Table 57. Mexico Tuberculosis Diagnostics, by End User USD Million (2018-2023)
  • Table 58. Company Basic Information, Sales Area and Its Competitors
  • Table 59. Company Basic Information, Sales Area and Its Competitors
  • Table 60. Company Basic Information, Sales Area and Its Competitors
  • Table 61. Company Basic Information, Sales Area and Its Competitors
  • Table 62. Company Basic Information, Sales Area and Its Competitors
  • Table 63. Company Basic Information, Sales Area and Its Competitors
  • Table 64. Company Basic Information, Sales Area and Its Competitors
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. South America Tuberculosis Diagnostics, by Country USD Million (2025-2030)
  • Table 70. South America Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 71. South America Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 72. Brazil Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 73. Brazil Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 74. Argentina Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 75. Argentina Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 76. Rest of South America Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 77. Rest of South America Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 78. Asia Pacific Tuberculosis Diagnostics, by Country USD Million (2025-2030)
  • Table 79. Asia Pacific Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 80. Asia Pacific Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 81. China Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 82. China Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 83. Japan Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 84. Japan Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 85. India Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 86. India Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 87. South Korea Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 88. South Korea Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 89. Taiwan Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 90. Taiwan Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 91. Australia Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 92. Australia Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 93. Rest of Asia-Pacific Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 94. Rest of Asia-Pacific Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 95. Europe Tuberculosis Diagnostics, by Country USD Million (2025-2030)
  • Table 96. Europe Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 97. Europe Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 98. Germany Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 99. Germany Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 100. France Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 101. France Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 102. Italy Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 103. Italy Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 104. United Kingdom Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 105. United Kingdom Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 106. Netherlands Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 107. Netherlands Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 108. Rest of Europe Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 109. Rest of Europe Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 110. MEA Tuberculosis Diagnostics, by Country USD Million (2025-2030)
  • Table 111. MEA Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 112. MEA Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 113. Middle East Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 114. Middle East Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 115. Africa Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 116. Africa Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 117. North America Tuberculosis Diagnostics, by Country USD Million (2025-2030)
  • Table 118. North America Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 119. North America Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 120. United States Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 121. United States Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 122. Canada Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 123. Canada Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 124. Mexico Tuberculosis Diagnostics, by Test USD Million (2025-2030)
  • Table 125. Mexico Tuberculosis Diagnostics, by End User USD Million (2025-2030)
  • Table 126. Research Programs/Design for This Report
  • Table 127. Key Data Information from Secondary Sources
  • Table 128. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. South America Tuberculosis Diagnostics Share (%), by Country
  • Figure 5. Asia Pacific Tuberculosis Diagnostics Share (%), by Country
  • Figure 6. Europe Tuberculosis Diagnostics Share (%), by Country
  • Figure 7. MEA Tuberculosis Diagnostics Share (%), by Country
  • Figure 8. North America Tuberculosis Diagnostics Share (%), by Country
  • Figure 9. Global Tuberculosis Diagnostics share by Players 2023 (%)
  • Figure 10. Global Tuberculosis Diagnostics share by Players (Top 3) 2023(%)
  • Figure 11. Global Tuberculosis Diagnostics share by Players (Top 5) 2023(%)
  • Figure 12. BCG Matrix for key Companies
  • Figure 13. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 14. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2023
  • Figure 15. Hologic Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 16. Hologic Corporation (United States) Revenue: by Geography 2023
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 19. Alere, Inc., Becton (United States) Revenue, Net Income and Gross profit
  • Figure 20. Alere, Inc., Becton (United States) Revenue: by Geography 2023
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 25. Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Dickinson and Company (United States) Revenue: by Geography 2023
  • Figure 27. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 29. Cepheid (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cepheid (United States) Revenue: by Geography 2023
  • Figure 31. Mylan N.V (United States) Revenue, Net Income and Gross profit
  • Figure 32. Mylan N.V (United States) Revenue: by Geography 2023
  • Figure 33. Hain Life science GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Hain Life science GmbH (Germany) Revenue: by Geography 2023
  • Figure 35. South America Tuberculosis Diagnostics Share (%), by Country
  • Figure 36. Asia Pacific Tuberculosis Diagnostics Share (%), by Country
  • Figure 37. Europe Tuberculosis Diagnostics Share (%), by Country
  • Figure 38. MEA Tuberculosis Diagnostics Share (%), by Country
  • Figure 39. North America Tuberculosis Diagnostics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific, Inc. (United States)
  • Hologic Corporation (United States)
  • Abbott Laboratories (United States)
  • Alere, Inc., Becton (United States)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • Dickinson and Company (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Cepheid (United States)
  • Mylan N.V (United States)
  • Hain Life science GmbH (Germany)
Additional players considered in the study are as follows:
Eli Lilly and Company (United States) , Qiagen (Germany) , BioMerieux SA (France) , Sanofi (France)
Select User Access Type

Key Highlights of Report


Jan 2024 243 Pages 71 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tuberculosis Diagnostics research Quantitative research analysis
Global Tuberculosis Diagnostics research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Thermo Fisher Scientific, Inc. (United States), Hologic Corporation (United States), Abbott Laboratories (United States), Alere, Inc., Becton (United States), Pfizer Inc. (United States), Johnson & Johnson (United States), Dickinson and Company (United States), F. Hoffmann-La Roche AG (Switzerland), Cepheid (United States), Mylan N.V (United States) and Hain Life science GmbH (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growth in R&D towards New Drug Development " is seen as one of major influencing trends for Tuberculosis Diagnostics Market during projected period 2023-2030.
The Tuberculosis Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Tuberculosis Diagnostics research Report?

Have a Query? Click Here

Other Related Reports

Cytogenetics Comprehensive Study by Type (Consumables, Testing Kits, Media, and Reagents, Probes, Others (Affinity Reagents and Stains), Instruments, Software & Services), Application (Genetic Disord...
$ 3750
Cosmetic Surgery Comprehensive Study by Type (Surgical Procedure, Non-surgical Procedure), Application (Liposuction, Eyelid and Nose Surgery, Body Contouring (Tummy Tuck, Breast Lift, Others), Facial...
$ 3650
Cell Expansion Comprehensive Study by Type (Consumables, Reagents, Media & Serum, Disposables (Tissue Culture Flasks, Bioreactor Accessories, and Others), Instruments (Cell Expansion Supporting Equip...
$ 3750
Acute Myeloid Leukemia Therapeutics Comprehensive Study by Type (Pipeline Drugs, Chemotherapy Drugs, Chemotherapy Regimens), Application (Hospitals, Clinics, Home Care), Drug Type (Bosutinib, Vidaza,...
$ 3750
Alopecia Comprehensive Study by Type (Oral treatment, Topical treatment, Other treatment), Application (Homecare Settings, Dermatology Clinics, Others (Salons)), Treatment (Vitamins and Supplements, ...
$ 3450
Endometriosis Treatment Comprehensive Study by Type (Gonadotropins releasing hormone agonists, Progestin, Non-steroidal anti-inflammatory drugs, Oral contraceptive pills), Application (Hospital pharm...
$ 3450